Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7599111rdf:typepubmed:Citationlld:pubmed
pubmed-article:7599111lifeskim:mentionsumls-concept:C0023418lld:lifeskim
pubmed-article:7599111lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:7599111lifeskim:mentionsumls-concept:C0312738lld:lifeskim
pubmed-article:7599111lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:7599111pubmed:issue4lld:pubmed
pubmed-article:7599111pubmed:dateCreated1995-8-10lld:pubmed
pubmed-article:7599111pubmed:abstractTextA new pre-B cell leukemia cell line, NALM-26, was established from the peripheral blood of a 24-year-old male patient with acute pre-B cell leukemia. NALM-26 is unique in its expression of T cell-associated CD5 and myeloid cell-associated CD13 antigens. Interleukin-7 (IL-7) receptor (CDw127) was detected by flow cytometric analysis. After PMA treatment, NALM-26 was induced to express CD20, CD25 and CD28, and to increase its expression of both CD5 and CD13. The expression of CDw127 was down-modulated.lld:pubmed
pubmed-article:7599111pubmed:languageenglld:pubmed
pubmed-article:7599111pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7599111pubmed:citationSubsetIMlld:pubmed
pubmed-article:7599111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7599111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7599111pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7599111pubmed:statusMEDLINElld:pubmed
pubmed-article:7599111pubmed:monthDeclld:pubmed
pubmed-article:7599111pubmed:issn0914-7470lld:pubmed
pubmed-article:7599111pubmed:authorpubmed-author:MatsuoYYlld:pubmed
pubmed-article:7599111pubmed:authorpubmed-author:AdachiTTlld:pubmed
pubmed-article:7599111pubmed:authorpubmed-author:TsubotaTTlld:pubmed
pubmed-article:7599111pubmed:issnTypePrintlld:pubmed
pubmed-article:7599111pubmed:volume7lld:pubmed
pubmed-article:7599111pubmed:ownerNLMlld:pubmed
pubmed-article:7599111pubmed:authorsCompleteYlld:pubmed
pubmed-article:7599111pubmed:pagination221-6lld:pubmed
pubmed-article:7599111pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:meshHeadingpubmed-meshheading:7599111-...lld:pubmed
pubmed-article:7599111pubmed:year1994lld:pubmed
pubmed-article:7599111pubmed:articleTitleEstablishment and characterization of new pre-B cell leukemia cell line NALM-26.lld:pubmed
pubmed-article:7599111pubmed:affiliationFujisaki Cell Center, Hayashibara Biochemical Labs, Inc., Okayama.lld:pubmed
pubmed-article:7599111pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7599111pubmed:publicationTypeCase Reportslld:pubmed